Search for: "NOVARTIS PHARMA V TEVA PHARMA"
Results 1 - 20
of 139
Sort by Relevance
|
Sort by Date
6 Jul 2023, 2:55 am
Although the Court of Appeal was clear, in Neurim v Generics [2020] EWCA Civ 793, that deciding to uphold the lower court’s decision not to grant a pharmaceutical patent PI was based on the specific facts of that case, the Patents Court has subsequently refused two further pharmaceutical PIs (Neurim v Teva [2022] EWHC 954 (Pat) and [2022] EWHC 1641(Pat), and Novartis v Teva [2022] EWHC 959 (Ch)). [read post]
5 Apr 2023, 5:18 am
Similarly, Hacon HHJ stated in Teva v Novartis [2022] EWHC 2847 (Pat): “It seems that there was little or no interaction between Novartis’ three experts during the preparation of their evidence. [read post]
22 Dec 2022, 7:59 am
Vidal (patentability of AI-created inventions) Novartis v. [read post]
26 Sep 2022, 4:49 am
Skinny Label Infringement in Teva Pharmaceuticals USA, Inc. v. [read post]
13 Dec 2021, 12:49 am
Teva also argued for good measure that the SPC was invalid under Article 3(a) and 3(d). [read post]
26 Oct 2020, 2:49 am
Joining the majority of European courts, the Paris Court of Justice ruled that Eli Lilly’s patent, which relates to the combined administration of pemetrexed disodium and vitamin B12, was infringed by the marketing of Fresenius’ pemetrexed diacid. [read post]
30 Apr 2020, 12:59 pm
Lastly, the CJEU’s judgment in Royalty Pharma also confirms that the test established by the Court in Teva v. [read post]
30 Apr 2019, 7:22 am
Final panellist Jürgen Dressel (ex- Novartis Pharma AG) explained that, going back to basics, the SPC is meant to be a reward for R&D and there should be legal certainty and a harmonised situation for the international market. [read post]
29 Jun 2018, 11:13 am
In its ruling, the Court ordered Teva to pay Novartis more than €13,000,000 as an advance on damages (€5,846,628 to Novartis Pharma AG, the Swiss company which owns the patent, and €7,308,285 to Novartis Pharma SAS, the French licensee). [read post]
3 Aug 2015, 5:10 am
Pick one of those and it will surely work (albeit it would be a mere arbitrary, non-inventive selection of the type discussed in Actavis v Novartis [2010]). [read post]
3 May 2015, 10:33 pm
With this note, he provides further food for thought on patent law’s complexity, from Bilski to Teva v Leo Pharma, to the relation between patent law and economics. [read post]
27 Apr 2015, 10:56 am
It has been all quiet on the pharma patent front since the beginning of March (when the epic series of first instance decisions on Swiss form claims came to and end: see here, here, here and here), and so this moggy was delighted when there fell into his paws the decision of Mr Justice Arnold in Novartis v Focus, Actavis, Teva [2015] EWHC 1068 (Pat).The case concerns a transdermal patch for rivastigmine, which is acetylcholinesterase (AChE) inhibitor… [read post]
23 Feb 2015, 2:55 am
| Dutch diverge with English as Novartis prevails on Zoledronic Acid in Netherlands | Slogan and TMs | The coffee capsule wars | Declining public trust in innovation | IPEC’s ruling in Global Flood Defence Systems & Another v Van den Noort Innovations BV & Others | Again on CJEU ruling in Case C-419/13 Art & Allposters | Biotech financing: the risk components, ‘going long’ and patents as knowledge currency. [read post]
16 Feb 2015, 1:44 am
| Dutch diverge with English as Novartis prevails on Zoledronic Acid in Netherlands | Slogan and TMs | The coffee capsule wars | Declining public trust in innovation | IPEC’s ruling in Global Flood Defence Systems & Another v Van den Noort Innovations BV & Others | Again on CJEU ruling in Case C-419/13 Art & Allposters | Biotech financing: the risk components, ‘going long’ and patents as knowledge currency. [read post]
9 Feb 2015, 1:15 am
| Dutch diverge with English as Novartis prevails on Zoledronic Acid in Netherlands | Slogan and TMs | The coffee capsule wars | Declining public trust in innovation | IPEC’s ruling in Global Flood Defence Systems & Another v Van den Noort Innovations BV & Others | Again on CJEU ruling in Case C-419/13 Art & Allposters | Biotech financing: the risk components, ‘going long’ and patents as knowledge currency. [read post]
2 Feb 2015, 2:20 am
* Dutch diverge with English as Novartis prevails on Zoledronic Acid in NetherlandsKatfriend Rutger M. [read post]
21 Oct 2014, 12:00 am
The author is occasional and much-appreciated guest contributor Suleman Ali (Holly IP), who writes as follows:Teva UK Limited & Teva Pharmaceuticals Limited v Leo Pharma A/S & Leo Laboratories Limited[2014] EWHC 3096 (Pat) is a decision by Mr Justice Birss in the Patents Court, England and Wales. [read post]
24 Feb 2014, 11:19 am
It's unattractive when compared with bright sparkly pharma names like Actavis, Astellas, AstraZeneca, Novartis, Solvay or Teva. [read post]
10 Nov 2013, 6:37 am
Pravin then alluded to decisions involving patents owned by Pfizer and Merck, in which the outcome was rather better for the proprietary pharma sector. [read post]
13 Feb 2013, 11:49 pm
The invalidation was pursuant to a law suit bought by BMS (the patentee) against Teva, a leading Israeli generic company. [read post]
